The company focuses on discovering new therapeutic approaches for tumors that lack effective treatment, such as pancreatic adenocarcinomas, by using an oncolytic adenovirus technology platform to design agents that replicate and self-amplify exclusively in tumor cells. VCN Biosciences' dedication to research and development of pharmaceuticals has resulted in the creation of new treatments for refractory tumors, helping healthcare institutes to provide better care for patients.